Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling

Cancer Research

Volumn 73, Issue 18, 2013, Pages 5633-5646

  Fang, Lei Ya ^a   Izumi, Kouji ^a   Lai, Kuo Pao ^a   Liang, Liang ^a   Li, Lei ^a   Miyamoto, Hiroshi ^a   Lin, Wen Jye ^a,b   Chang, Chawnshang ^a,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CARBON TETRACHLORIDE; CHEMOKINE RECEPTOR; CYTOKINE ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL;

ARTICLE; CARCINOGENESIS; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHEMOKINE CCL4; CURCUMIN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84884752495     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3228     Document Type: Article

References (38)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124:823-35.
3. Perletti G, Montanari E, Vral A, Gazzano G, Marras E, Mione S, et al. Inflammation, prostatitis, proliferative inflammatory atrophy: 'fertile ground' for prostate cancer development? Mol Med Report 2010;3: 3-12.
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7: 256-69.
5. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18:349-55.
6. Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC, Lin WJ, et al. Monocyte/ macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 2009;119:3739-51.
7. Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007;13: 348-53.
8. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124: 615-29.
9. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005;15:365-77.
10. Hu WY, Shi GB, Lam HM, Hu DP, Ho SM, Madueke IC, et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology 2011;152:2150-63.
11. Chu JH, Yu S, Hayward SW, Chan FL. Development of a threedimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer. Prostate 2009;69:428-42.
12. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 2007;27:4444-53.
13. Jiang M, Jerome WG, Hayward SW. Autophagy in nuclear receptor PPARgamma-deficient mouse prostatic carcinogenesis. Autophagy 2010;6:175-6.
14. Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, et al. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 2010;17: 469-81.
15. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor- mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60:2132-5.
16. Lai KP, Yamashita S, Huang CK, Yeh S, Chang C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of proinflammatory cytokines/chemokines. EMBO Mol Med 2012;4:791-807.
17. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-47.
18. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Ptendeficient tumorigenesis. Nature 2005;436:725-30.
19. Lai KP, Yamashita S, Vitkus S, Shyr CR, Yeh S, Chang C. Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor. Mol Endocrinol 2012;26:52-66.
20. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgendeprivation therapy of prostate cancer fails. Oncogene 2010;29: 3593-604.
21. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-55.
22. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999;8:265-77.
23. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99:558-68.
24. Elkahwaji JE, Hauke RJ, Brawner CM. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer 2009;101:1740-8.
25. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
26. Sica A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 2010;32:153-8.
27. Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene 2009;28:3892-902.
28. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009;4: e6562.
29. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
30. Mukhopadhyay UK, Mooney P, Jia L, Eves R, Raptis L, Mak AS. Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion. Mol Cell Biol 2010;30:4980-95.
31. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-beta, PI3K/Akt, and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009;417: 411-21.
32. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275: 1943-7.
33. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003;3:117-30.
34. Lopez-Novoa JM, Nieto M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009;1:303-14.
35. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012;72:1878-89.
36. Yamashita S, Lai KP, Chuang KL, Miyamoto H, Tochigi T, Pang ST, et al. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors. Neoplasia 2012;14:74-83.
37. Lin TH, Niu Y, Lee SO, Xu D, Liang L, Li L, et al. Differential androgen deprivation therapies with anti-androgens asodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9 lead to promotion versus suppression of prostate cancer metastasis. JBC 2013;288:19359-69.
38. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C, et al. Anti-androgen receptor of ASC-J9 vs anti-androgens casodex or MDV3100 leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death and Disease 2013; in press.